Search Result

Search Result

Results for "

CP 690550

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Bacterial (2) Fungal (2) Influenza Virus (2) Isotope-Labeled Compounds (5) JAK (6)
By Research Areas:	Cancer (8) Infection (2) Inflammation/Immunology (9)

9

Inhibitors & Agonists

6

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Tofacitinib 60+ Cited Publications Tasocitinib; CP-690550	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib citrate 60+ Cited Publications Tasocitinib citrate; CP-690550 citrate	JAK Apoptosis Bacterial Fungal Influenza Virus	Infection Inflammation/Immunology Cancer
Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Tofacitinib-d3 citrate Tasocitinib-d₃ citrate; CP-690550-d₃ citrate	Isotope-Labeled Compounds JAK Apoptosis Bacterial Fungal Influenza Virus	Infection Inflammation/Immunology Cancer
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Tofacitinib-13C3 Tasocitinib-¹³C₃; CP-690550-¹³C₃	JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

CP-690550A	JAK	Inflammation/Immunology
CP-690550A is an analogue of Tofacitinib (HY-40354). CP-690550A is a dual inhibitor of JAK2 and JAK3 .

Tofacitinib-d3 Tasocitinib-d₃; CP-690550-d₃	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib-d₃ (Tasocitinib-d₃) is deuterium labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C Tasocitinib-¹³C; CP-690550-¹³C	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib- ¹³C (Tasocitinib- ¹³C) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C,d3 Tasocitinib-¹³C,d₃; CP-690550-¹³C,d₃	Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C3,15N Tasocitinib-¹³C₃,¹⁵N; CP-690550-¹³C₃,¹⁵N	Isotope-Labeled Compounds JAK Apoptosis	Inflammation/Immunology Cancer
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Cat. No.	Product Name	Chemical Structure

Tofacitinib-d3 citrate
Tofacitinib-d₃ (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Tofacitinib-13C3
Tofacitinib- ¹³C₃ is the ¹³C-labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.

Tofacitinib-d3
Tofacitinib-d₃ (Tasocitinib-d₃) is deuterium labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C
Tofacitinib- ¹³C (Tasocitinib- ¹³C) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C,d3
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Tofacitinib-13C3,15N
Tofacitinib- ¹³C₃, ¹⁵N (Tasocitinib- ¹³C₃, ¹⁵N) is ¹³C and ¹⁵N labeled Tofacitinib. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

MedChemExpress Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator; DNA/RNA sequence conversion tools

Subscribe to our E-newsletter

Name
Email *

	Sorry, but the email address you supplied was invalid.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2025 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us